Tags

Type your tag names separated by a space and hit enter

Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial.
JAMA 2012; 308(13):1333-9JAMA

Abstract

CONTEXT

Observational studies have reported an inverse association between serum 25-hydroxyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs). However, results of clinical trials of vitamin D supplementation have been inconclusive.

OBJECTIVE

To determine the effect of vitamin D supplementation on incidence and severity of URTIs in healthy adults.

DESIGN, SETTING, AND PARTICIPANTS

Randomized, double-blind, placebo-controlled trial conducted among 322 healthy adults between February 2010 and November 2011 in Christchurch, New Zealand.

INTERVENTION

Participants were randomly assigned to receive an initial dose of 200,000 IU oral vitamin D3, then 200,000 IU 1 month later, then 100,000 IU monthly (n = 161), or placebo administered in an identical dosing regimen (n = 161), for a total of 18 months.

MAIN OUTCOME MEASURES

The primary end point was number of URTI episodes. Secondary end points were duration of URTI episodes, severity of URTI episodes, and number of days of missed work due to URTI episodes.

RESULTS

The mean baseline 25-OHD level of participants was 29 (SD, 9) ng/mL. Vitamin D supplementation resulted in an increase in serum 25-OHD levels that was maintained at greater than 48 ng/mL throughout the study. There were 593 URTI episodes in the vitamin D group and 611 in the placebo group, with no statistically significant differences in the number of URTIs per participant (mean, 3.7 per person in the vitamin D group and 3.8 per person in the placebo group; risk ratio, 0.97; 95% CI, 0.85-1.11), number of days of missed work as a result of URTIs (mean, 0.76 days in each group; risk ratio, 1.03; 95% CI, 0.81-1.30), duration of symptoms per episode (mean, 12 days in each group; risk ratio, 0.96; 95% CI, 0.73-1.25), or severity of URTI episodes. These findings remained unchanged when the analysis was repeated by season and by baseline 25-OHD levels.

CONCLUSION

In this trial, monthly administration of 100,000 IU of vitamin D did not reduce the incidence or severity of URTIs in healthy adults.

TRIAL REGISTRATION

anzctr.org.au Identifier: ACTRN12609000486224.

Authors+Show Affiliations

Department of Pathology, University of Otago, Christchurch, PO Box 4345, Christchurch 8011, New Zealand. david.murdoch@otago.ac.nzNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23032549

Citation

Murdoch, David R., et al. "Effect of Vitamin D3 Supplementation On Upper Respiratory Tract Infections in Healthy Adults: the VIDARIS Randomized Controlled Trial." JAMA, vol. 308, no. 13, 2012, pp. 1333-9.
Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333-9.
Murdoch, D. R., Slow, S., Chambers, S. T., Jennings, L. C., Stewart, A. W., Priest, P. C., ... Scragg, R. (2012). Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA, 308(13), pp. 1333-9. doi:10.1001/jama.2012.12505.
Murdoch DR, et al. Effect of Vitamin D3 Supplementation On Upper Respiratory Tract Infections in Healthy Adults: the VIDARIS Randomized Controlled Trial. JAMA. 2012 Oct 3;308(13):1333-9. PubMed PMID: 23032549.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. AU - Murdoch,David R, AU - Slow,Sandy, AU - Chambers,Stephen T, AU - Jennings,Lance C, AU - Stewart,Alistair W, AU - Priest,Patricia C, AU - Florkowski,Christopher M, AU - Livesey,John H, AU - Camargo,Carlos A, AU - Scragg,Robert, PY - 2012/10/4/entrez PY - 2012/10/4/pubmed PY - 2012/10/10/medline SP - 1333 EP - 9 JF - JAMA JO - JAMA VL - 308 IS - 13 N2 - CONTEXT: Observational studies have reported an inverse association between serum 25-hydroxyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs). However, results of clinical trials of vitamin D supplementation have been inconclusive. OBJECTIVE: To determine the effect of vitamin D supplementation on incidence and severity of URTIs in healthy adults. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted among 322 healthy adults between February 2010 and November 2011 in Christchurch, New Zealand. INTERVENTION: Participants were randomly assigned to receive an initial dose of 200,000 IU oral vitamin D3, then 200,000 IU 1 month later, then 100,000 IU monthly (n = 161), or placebo administered in an identical dosing regimen (n = 161), for a total of 18 months. MAIN OUTCOME MEASURES: The primary end point was number of URTI episodes. Secondary end points were duration of URTI episodes, severity of URTI episodes, and number of days of missed work due to URTI episodes. RESULTS: The mean baseline 25-OHD level of participants was 29 (SD, 9) ng/mL. Vitamin D supplementation resulted in an increase in serum 25-OHD levels that was maintained at greater than 48 ng/mL throughout the study. There were 593 URTI episodes in the vitamin D group and 611 in the placebo group, with no statistically significant differences in the number of URTIs per participant (mean, 3.7 per person in the vitamin D group and 3.8 per person in the placebo group; risk ratio, 0.97; 95% CI, 0.85-1.11), number of days of missed work as a result of URTIs (mean, 0.76 days in each group; risk ratio, 1.03; 95% CI, 0.81-1.30), duration of symptoms per episode (mean, 12 days in each group; risk ratio, 0.96; 95% CI, 0.73-1.25), or severity of URTI episodes. These findings remained unchanged when the analysis was repeated by season and by baseline 25-OHD levels. CONCLUSION: In this trial, monthly administration of 100,000 IU of vitamin D did not reduce the incidence or severity of URTIs in healthy adults. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12609000486224. SN - 1538-3598 UR - https://www.unboundmedicine.com/medline/citation/23032549/Effect_of_vitamin_D3_supplementation_on_upper_respiratory_tract_infections_in_healthy_adults:_the_VIDARIS_randomized_controlled_trial_ L2 - https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2012.12505 DB - PRIME DP - Unbound Medicine ER -